Gu, Shengqing Stan
Wang, Xiaoqing
Hu, Xihao
Jiang, Peng
Li, Ziyi
Traugh, Nicole
Bu, Xia
Tang, Qin
Wang, Chenfei
Zeng, Zexian
Fu, Jingxin
Meyer, Cliff
Zhang, Yi
Cejas, Paloma
Lim, Klothilda
Wang, Jin
Zhang, Wubing
Tokheim, Collin
Sahu, Avinash Das
Xing, Xiaofang
Kroger, Benjamin
Ouyang, Zhangyi
Long, Henry
Freeman, Gordon J.
Brown, Myles
Liu, X. Shirley http://orcid.org/0000-0003-4736-7339
Funding for this research was provided by:
National Institutes of Health (R01 CA234018, U01 CA226196)
Article History
Received: 7 April 2020
Accepted: 15 September 2020
First Online: 15 October 2020
Ethics approval and consent to participate
: All animal procedures were carried out under the DFCI Institutional Animal Care and Use Committee (IACUC) protocol and were in accordance with the IACUC standards for the welfare of animals.
: Not applicable.
: XSL is a cofounder, board, and SAB member of GV20 Oncotherapy and its subsidiaries; SAB of 3DMed Care; consultant for Genentech; and stock holder of BMY, TMO, WBA, ABT, ABBV, and JNJ, and received research funding from Takeda and Sanofi.MB is a consultant to and receives sponsored research support from Novartis. MB is a consultant to and serves on the scientific advisory boards of Kronos Bio, H3 Biomedicine, and GV20 Oncotherapy.GJF has patents/pending royalties on the PD-1/PD-L1 pathway from Roche, Merck MSD, Bristol-Myers-Squibb, Merck KGA, Boehringer-Ingelheim, AstraZeneca, Dako, Leica, Mayo Clinic, and Novartis. GJF has served on advisory boards for Roche, Bristol-Myers-Squibb, Xios, Origimed, Triursus, iTeos, NextPoint, IgM, Jubilant, and GV20. GJF has equity in Nextpoint, Triursus, Xios, iTeos, IgM, and GV20.